SCPHARMACEUTICALS INC. - COMMON STOCK

scPharmaceuticals Inc. Announces Appointment of Rachael Nokes as Chief Financial Officer

19 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

scPharmaceuticals to Participate in the 12th Annual LifeSci Partners Corporate Access Event

14 Dec 2022 07:00:01 By Nasdaq GlobeNewswire

scPharmaceuticals Announces Pricing of $50 Million Public Offering

22 Nov 2022 07:01:42 By Nasdaq GlobeNewswire

scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock

21 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

scPharmaceuticals Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update

09 Nov 2022 15:05:03 By Nasdaq GlobeNewswire

scPharmaceuticals to Participate in the Jefferies London Healthcare Conference

02 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

scPharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 9, 2022

26 Oct 2022 07:00:02 By Nasdaq GlobeNewswire

UPDATE - scPharmaceuticals Announces FDA Approval of FUROSCIX® (furosemide injection), the First and Only Self-administered, Subcutaneous Loop Diuretic for the At-home Treatment of Congestion in Chronic Heart Failure

10 Oct 2022 08:41:38 By Nasdaq GlobeNewswire

scPharmaceuticals Announces $100 Million Debt Financing Agreement with Oaktree

10 Oct 2022 07:05:00 By Nasdaq GlobeNewswire

scPharmaceuticals Announces FDA Approval of FUROSCIX® (furosemide injection), the First and Only Self-administered, Subcutaneous Loop Diuretic for the At-home Treatment of Congestion in Chronic Heart Failure

10 Oct 2022 07:00:00 By Nasdaq GlobeNewswire

scPharmaceuticals Announces Data Presentations at the Heart Failure Society of America 2022 Annual Scientific Meeting

30 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

scPharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

01 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

scPharmaceuticals Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

09 Aug 2022 06:00:01 By Nasdaq GlobeNewswire

scPharmaceuticals Inc. to Participate in the Maxim Group LLC Late-Stage Advancements in Heart Failure Therapeutics and Management Panel Discussion

13 Jul 2022 07:00:01 By Nasdaq GlobeNewswire

scPharmaceuticals Inc. Announces Positive Results from the AT HOME-HF Phase 2 Pilot Study in Heart Failure

12 Jul 2022 07:00:02 By Nasdaq GlobeNewswire

scPharmaceuticals Inc. to Host FUROSCIX® (furosemide) 80mg/10mL for Subcutaneous Administration Commercial Day: An Investigational Treatment for Heart Failure Patients

30 Jun 2022 07:00:02 By Nasdaq GlobeNewswire

scPharmaceuticals Inc. Announces Abstracts Accepted for Presentation at the American Association of Heart Failure Nurses 18th Annual Meeting

07 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

scPharmaceuticals to Present at the Jefferies Healthcare Conference

24 May 2022 07:00:01 By Nasdaq GlobeNewswire

scPharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

17 May 2022 07:00:01 By Nasdaq GlobeNewswire

scPharmaceuticals Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

16 May 2022 06:10:00 By Nasdaq GlobeNewswire